BerGenBio continued to strengthen the data package for bemcentinib with the results presented at various conferences during Q219, including AACR and ASCO. Importantly, the data continues to support the hypotheses that bemcentinib has promising activity MDS/AML and NSCLC, and can work synergistically with pembrolizumab (Keytruda) in NSCLC.
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Refining the route ahead
- Published:
20 Aug 2019 -
Author:
Mick Cooper PhD -
Pages:
3
BerGenBio continued to strengthen the data package for bemcentinib with the results presented at various conferences during Q219, including AACR and ASCO. Importantly, the data continues to support the hypotheses that bemcentinib has promising activity MDS/AML and NSCLC, and can work synergistically with pembrolizumab (Keytruda) in NSCLC.